Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus.
Conditions: Systemic Lupus Erythematosus Interventions: Diagnostic Test: CBC; Diagnostic Test: Antinuclear Antibody tests (ANA); Diagnostic Test: Rest of ANA profile; Diagnostic Test: C3 and C4 complement level.; Diagnostic Test: Anti phospholipid marker; Diagnostic Test: Serum creatinine and Alb/create ratio; Other: 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.; Other: SLEDAI scores Sponsors: Sohag University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
Fibrinogen to Albumin Ratio (FAR) as a Predictive Biomarker for Lupus Nephritis (LN)
Conditions: Lupus Nephritis Interventions: Diagnostic Test: fibronigin to albumin ratio Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials
Renal Assessment for Early Detection of Renal Impairment in Systemic Sclerosis and Systemic Lupus Erythematosus Patients
Conditions: Systemic Sclerosis and Systemic Lupus Erythematous Interventions: Device: Renal multi-parametric MRI, Renal doppler ultrasound, Serum CD147 Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
FKC288 in Participants With Autoimmune Kidney Diseases
Conditions: Lupus Nephritis, ANCA-associated Vasculitis, Membranous Nephropathy, IgG4-related Diseases Interventions: Drug: FKC288 Sponsors: Nanjing University School of Medicine Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
Conditions: Lupus Nephritis; ANCA Associated Vasculitis Interventions: Drug: PRG-1801 （CAR-T against BCMA） Sponsors: Lingli Dong; Shenzhen Pregene Biopharma Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis
Conditions: Lupus Nephritis - WHO Class III; Lupus Nephritis - WHO Class IV Interventions: Drug: AB-101; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Rituximab Sponsors: Artiva Biotherapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
The Effect of Listening to Qur'an Recital on Quality of Life in Systemic Lupus Erythematosus Patients
Conditions: Quality of Life Interventions: Other: Listening to Qur ' an Recital Sponsors: Indonesia University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2024 Category: Research Source Type: clinical trials
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects With Discoid Lupus Erythematosus
Conditions: Discoid Lupus Erythematosus Interventions: Drug: Ruxolitinib 1.5% cream without occlusion; Drug: Ruxolitinib 1.5% cream under occlusion at night Sponsors: Innovaderm Research Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 15, 2024 Category: Research Source Type: clinical trials
(Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-ds DNA Antibodies) and Relation to Depression and Anxiety in SLE
Conditions: Systemic Lupus Erythematosus Interventions: Diagnostic Test: Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies Sponsors: Sohag University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
A Study of CNTY-101 in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus Interventions: Biological: CNTY-101; Biological: IL-2; Drug: Lymphodepleting Chemotherapy Sponsors: Century Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Conditions: Systemic Lupus Erythematosus (SLE); Immune-Mediated Necrotizing Myopathy; Neuromyelitis Optica Spectrum Disorders; Multiple Sclerosis-Relapsing-Remitting Interventions: Biological: CD20/BCMA-directed CAR-T cells Sponsors: RenJi Hospital; AbelZeta Pharma Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus
Conditions: Systemic Lupus Erythematosus Interventions: Drug: Gusacitinib Sponsors: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
Gradual Withdrawal of Low-dose Glucocorticoid in Clinically Quiescent Systemic Lupus Erythematosus.
Conditions: Systemic Lupus Erythematosus, SLE Interventions: Behavioral: Glucocorticoid withdrawal group; Behavioral: Glucocorticoid maintenance group Sponsors: Phramongkutklao College of Medicine and Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus of Childhood (Disorder) Interventions: Behavioral: TEACH Sponsors: Michigan State University; United States Department of Defense; The Hospital for Sick Children; Seattle Children ' s Hospital; Children ' s Hospital Medical Center, Cincinnati; Tulane University; University of Alabama at Birmingham; Helen DeVos Children ' s Hospital; Montefiore Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
Gut Microbiota Dysbiosis in Lupus Nephritis
Conditions: Gut Microbiota Dysbiosis in Lupus Nepheritis Interventions: Genetic: DNA extraction and PCR amplification Sponsors: Hager Zanaty Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
